Study 2018-02 (HTA) The cost-effectiveness of spending on innovative pharmaceutical specialties in oncology in recent years

Ongoing study - Medical progress does not stand still. Every year many new pharmaceuticals and other interventions are introduced on the market. In a context of limited budgetary means, the reimbursement of certain pharmaceutical specialties can mean that other healthcare interventions cannot be reimbursed (anymore). This is the so-called ‘displacement effect'. The KCE will examine the extent to which the expenditure in the last years on new pharmaceutical specialties in the field of oncology results in health gains.

Published on: